相似文献
1
Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature.
Clin Genitourin Cancer. 2014 Aug;12(4):e147-50. doi: 10.1016/j.clgc.2014.02.006. Epub 2014 Feb 28.
2
Can we rely on PET in the follow-up of advanced seminoma patients?
Urol Int. 2012;88(4):405-9. doi: 10.1159/000337056. Epub 2012 Apr 12.
3
FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Eur J Radiol. 2005 May;54(2):284-8. doi: 10.1016/j.ejrad.2004.07.012.
4
False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Urol Oncol. 2015 Jan;33(1):23.e15-23.e21. doi: 10.1016/j.urolonc.2014.09.019. Epub 2014 Nov 4.
5
Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Risk-adapted Approach.
Clin Oncol (R Coll Radiol). 2021 Jul;33(7):e315-e321. doi: 10.1016/j.clon.2021.01.009. Epub 2021 Feb 16.
6
[Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Rofo. 2004 Jan;176(1):76-84. doi: 10.1055/s-2004-814665.
7
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
Br J Cancer. 2002 Feb 12;86(4):506-11. doi: 10.1038/sj.bjc.6600122.
8
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Eur Urol. 2022 Aug;82(2):172-179. doi: 10.1016/j.eururo.2022.04.031. Epub 2022 May 20.
9
FDG PET for detection and therapy control of metastatic germ cell tumor.
J Nucl Med. 1998 May;39(5):815-22.
10
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
J Clin Oncol. 2001 Sep 1;19(17):3740-4. doi: 10.1200/JCO.2001.19.17.3740.
引用本文的文献
1
End-of-Treatment FDG PET-CT (EOT-PET) in Patients with Post-Chemotherapy Masses for Seminoma: Can We Avoid Further Intervention?
South Asian J Cancer. 2022 Aug 22;11(4):315-321. doi: 10.1055/s-0041-1735480. eCollection 2022 Oct.
2
Imaging of the scrotum: beyond sonography.
Insights Imaging. 2018 Apr;9(2):137-148. doi: 10.1007/s13244-017-0592-z. Epub 2018 Feb 15.
3
Intraoperative Molecular Imaging for Post-Chemotherapy Robot-Assisted Laparoscopic Resection of Seminoma Metastasis: A Case Report.
Clin Genitourin Cancer. 2017 Feb;15(1):e61-e64. doi: 10.1016/j.clgc.2016.09.007. Epub 2016 Sep 23.
本文引用的文献
1
[Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].
Urologe A. 2011 Mar;50(3):322-7. doi: 10.1007/s00120-010-2469-3.
2
Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma?
Can Urol Assoc J. 2010 Oct;4(5):E137-40. doi: 10.5489/cuaj.937.
3
Recurrent seminomas: clinical features and biologic implications.
Urol Oncol. 2012 Jul-Aug;30(4):494-501. doi: 10.1016/j.urolonc.2010.05.011. Epub 2010 Sep 6.
4
NCCN clinical practice guidelines in oncology: testicular cancer.
J Natl Compr Canc Netw. 2009 Jun;7(6):672-93. doi: 10.6004/jnccn.2009.0047.
5
The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
J Urol. 2008 Mar;179(3):936-40; discussion 940. doi: 10.1016/j.juro.2007.10.054. Epub 2008 Jan 22.
6
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.
Eur Urol. 2008 Mar;53(3):478-96. doi: 10.1016/j.eururo.2007.12.024. Epub 2007 Dec 26.
7
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.
Eur Urol. 2008 Mar;53(3):497-513. doi: 10.1016/j.eururo.2007.12.025. Epub 2007 Dec 26.
8
FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Eur J Radiol. 2005 May;54(2):284-8. doi: 10.1016/j.ejrad.2004.07.012.
9
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
J Clin Oncol. 2004 Mar 15;22(6):1034-9. doi: 10.1200/JCO.2004.07.188.
10
Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?
J Urol. 2003 Jun;169(6):2126-8. doi: 10.1097/01.ju.0000060121.33899.4b.
Zotero 插件